Viatris Slides Despite Higher 2026 Guidance as Supply Disruption Risks Remain in Focus

Viatris (VTRS) is down 7.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The selloff appears tied less to the headline quarter and more to investor concern about execution risks in the second half. Viatris posted revenue growth and raised its 2026 guidance, but the market may be focusing on expected product-supply disruption from its Nashik, India facility, plus a quarterly GAAP loss tied to the planned Tyrvaya rights sale.

Details:

Viatris reported second-quarter 2026 total revenue of about $3.8 billion, up 5% from a year earlier, and adjusted EPS of $0.69, showing solid operating performance.

The company raised the midpoint of its 2026 outlook for revenue, adjusted EBITDA and adjusted EPS, signaling confidence after the first half.

Management also said second-half 2026 revenue could be reduced by about $100 million to $150 million because of supply disruption tied to remediation work, FDA Form 483 observations, and earlier fire-related issues at the Nashik facility.

Reported results included a GAAP net loss of roughly $119 million, driven largely by a non-cash charge related to the planned sale of Tyrvaya product rights, which may have weighed on sentiment even though it does not reflect core operations.

Sources:

Viatris, SEC

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$VTRS Insider Trading Activity

$VTRS insiders have traded $VTRS stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $VTRS stock by insiders over the last 6 months:

PAUL CAMPBELL (See Remarks) has made 0 purchases and 2 sales selling 71,426 shares for an estimated $1,093,322.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive VTRS Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$VTRS Hedge Fund Activity

We have seen 444 institutional investors add shares of $VTRS stock to their portfolio, and 418 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRICE T ROWE ASSOCIATES INC /MD/ removed 13,215,766 shares (-16.7%) from their portfolio in Q1 2026, for an estimated $178,544,998
QUBE RESEARCH & TECHNOLOGIES LTD added 9,149,066 shares (+1767.3%) to their portfolio in Q1 2026, for an estimated $123,603,881
MARSHALL WACE, LLP added 8,946,958 shares (+2220.9%) to their portfolio in Q1 2026, for an estimated $120,873,402
RUBRIC CAPITAL MANAGEMENT LP added 8,000,000 shares (+31.4%) to their portfolio in Q1 2026, for an estimated $108,080,000
GOLDMAN SACHS GROUP INC added 7,597,529 shares (+124.1%) to their portfolio in Q1 2026, for an estimated $102,642,616
FRANKLIN RESOURCES INC added 4,660,845 shares (+512.9%) to their portfolio in Q1 2026, for an estimated $62,968,015
SG AMERICAS SECURITIES, LLC added 4,526,654 shares (+1581.9%) to their portfolio in Q1 2026, for an estimated $61,155,095

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$VTRS Price Targets

Multiple analysts have issued price targets for $VTRS recently. We have seen 3 analysts offer price targets for $VTRS in the last 6 months, with a median target of $20.0.

Here are some recent targets:

Glen Santangelo from Barclays set a target price of $22.0 on 05/19/2026
Chris Schott from JP Morgan set a target price of $18.0 on 05/08/2026
Srikripa Devarakonda from Truist Securities set a target price of $20.0 on 05/08/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.